The National Cancer Database (NCDB) offers a comprehensive dataset that includes both clinical and sociodemographic information, facilitating an in-depth analysis of treatment utilization trends, including those related to HER2-targeted therapies [11,12,13,14]. This evidence concerns the gene ERBB2 and cancer.